Flora Cimmino
Overview
Explore the profile of Flora Cimmino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
710
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Rosa C, Iommelli F, De Rosa V, Ercolano G, Sodano F, Tuccillo C, et al.
Biomedicines
. 2024 Apr;
12(4).
PMID: 38672164
Background: Lung cancer (LC), including both non-small (NSCLC) and small (SCLC) subtypes, is currently treated with a combination of chemo- and immunotherapy. However, predictive biomarkers to identify high-risk patients are...
2.
Pirone D, Lim J, Merola F, Miccio L, Mugnano M, Bianco V, et al.
Nat Photonics
. 2022 Dec;
16(12):851-859.
PMID: 36451849
Quantitative Phase Imaging (QPI) has gained popularity in bioimaging because it can avoid the need for cell staining, which in some cases is difficult or impossible. However, as a result,...
3.
Di Liello R, Cimmino F, Simon S, Giunta E, De Falco V, Martin-Martorell P
Explor Target Antitumor Ther
. 2022 Sep;
1(3):183-199.
PMID: 36046196
Immunotherapy has shifted the therapeutic landscape in thoracic cancers. However, assessment of biomarkers for patient selection and disease monitoring remain challenging, especially considering the lack of tissue sample availability for...
4.
Della Corte C, Cimmino F, Morgillo F
Explor Target Antitumor Ther
. 2022 Sep;
2(2):204-207.
PMID: 36046146
No abstract available.
5.
Cimmino F, Montella A, Tirelli M, Avitabile M, Lasorsa V, Visconte F, et al.
Cancer Cell Int
. 2022 Apr;
22(1):174.
PMID: 35488346
Background: FGFR1 regulates cell-cell adhesion and extracellular matrix architecture and acts as oncogene in several cancers. Potential cancer driver mutations of FGFR1 occur in neuroblastoma (NB), a neural crest-derived pediatric...
6.
Della Corte C, Fasano M, Ciaramella V, Cimmino F, Cardnell R, Gay C, et al.
J Exp Clin Cancer Res
. 2022 Mar;
41(1):109.
PMID: 35346313
Background: We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1 drug, and cetuximab, an anti-epidermal...
7.
Cardinale A, Cantalupo S, Lasorsa V, Montella A, Cimmino F, Succoio M, et al.
Hum Mol Genet
. 2021 Oct;
31(6):863-874.
PMID: 34605909
The 10q24.33 locus is known to be associated with susceptibility to cutaneous malignant melanoma (CMM), but the mechanisms underlying this association have been not extensively investigated. We carried out an...
8.
Cimmino F, Lasorsa V, Vetrella S, Iolascon A, Capasso M
Front Oncol
. 2020 Dec;
10:596191.
PMID: 33381456
Background: Liquid biopsies do not reflect the complete mutation profile of the tumor but have the potential to identify actionable mutations when tumor biopsies are not available as well as...
9.
Fasano M, Della Corte C, Di Liello R, Barra G, Sparano F, Viscardi G, et al.
ESMO Open
. 2020 Sep;
5(5):e000753.
PMID: 32912860
Background: Antibody-dependent cell-mediated cytotoxicity (ADCC) may mediate antitumour activity of IgG1-isotype monoclonal antibody (mAb), suggesting as potential treatment combination of IgG1-mAbs, anti-epidermal growth factor receptor cetuximab and anti-programmed death-ligand-1 avelumab....
10.
Lasorsa V, Cimmino F, Ognibene M, Mazzocco K, Erminio G, Morini M, et al.
NPJ Genom Med
. 2020 Apr;
5:18.
PMID: 32337068
Genomic aberrations of neuroblastoma occurring in late childhood and adolescence are still understudied. Publicly available DNA copy number profiles of 556 tumors (discovery set) and of 208 tumors obtained by...